Results 171 to 180 of about 48,191 (295)

Early‐Onset Mucocutaneous Findings and Isolated Progressive Thrombocytopenia in a Child With a DKC1 A353V Variant

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Dyskeratosis congenita (DC) is a rare telomere biology disorder characterized by mucocutaneous abnormalities and progressive bone marrow failure. We report a 10‐year‐old boy with a hemizygous DKC1 c.1058C > T (p.Ala353Val) variant who presented with unusually early mucocutaneous findings, including oral leukoplakia at 2 years of age, followed ...
Harun Kasapoğlu   +4 more
wiley   +1 more source

High‐Altitude Hypoxemia in Adults With Sickle Cell Disease (SCD)

open access: yes
American Journal of Hematology, Volume 101, Issue 7, Page 1665-1669, July 2026.
Mofiyin A. Obadina   +4 more
wiley   +1 more source

Pediatric Wilson Disease in Sudan: A Rare Case, Sudan Conflict and Diagnostic Challenges

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Wilson disease is rarely reported among African children. Wilson disease is due to a mutation in ATP7B on an autosomal recessive pattern, which causes defective copper excretion and copper accumulation in tissues such as liver and brain.
Amjed Abdu Ali Mohammed   +8 more
wiley   +1 more source

Pure Red Cell Aplasia as an Isolated Paraneoplastic Manifestation of Thymoma: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Thymomas are epithelial tumors of the anterior mediastinum and are frequently associated with paraneoplastic autoimmune disorders. Pure red cell aplasia (PRCA) is a rare but clinically significant complication, caused by immune‐mediated suppression of erythropoiesis.
Heba Amer   +8 more
wiley   +1 more source

Methotrexate Toxicity in a Patient With Renal Failure Despite a Normal Methotrexate Concentration: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Methotrexate (MTX) is a folate antagonist widely used as a disease‐modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA), as well as in several malignancies and autoimmune disorders. Although low‐dose MTX (5–20 mg/week) is generally considered safe, it has a narrow therapeutic index, and toxicity can occur even at therapeutic doses,
Fatemeh Afra   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy